Docoh
Loading...

TEVA Teva- Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Company profile

Ticker
TEVA
Exchange
CEO
Kaare Schultz
Employees
Incorporated
Location
Fiscal year end
Former names
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
SEC CIK

TEVA stock data

(
)

Calendar

10 Feb 21
18 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 2.18B 2.18B 2.18B 2.18B 2.18B 2.18B
Cash burn (monthly) (positive/no burn) (positive/no burn) (positive/no burn) 297.67M (positive/no burn) (positive/no burn)
Cash used (since last report) n/a n/a n/a 1.07B n/a n/a
Cash remaining n/a n/a n/a 1.1B n/a n/a
Runway (months of cash) n/a n/a n/a 3.7 n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
16 Mar 21 Mark Sabag Ordinary Shares Sell Dispose S No No 11.2195 127,244 1.43M 20,598
5 Mar 21 Eliyahu Sharon Kalif Restricted Share Units Ordinary Shares Grant Aquire A No No 0 85,551 0 85,551
5 Mar 21 Sven Dethlefs Restricted Share Units Ordinary Shares Grant Aquire A No No 0 99,809 0 99,809
5 Mar 21 Richard Daniell Restricted Share Units Ordinary Shares Grant Aquire A No No 0 90,304 0 90,304
5 Mar 21 Eric Drape Restricted Share Units Ordinary Shares Grant Aquire A No No 0 90,304 0 90,304
4 Mar 21 Sven Dethlefs Ordinary Shares Sell Dispose S No Yes 10.5661 6,012 63.52K 77,975.7
4 Mar 21 Sven Dethlefs Ordinary Shares Option exercise Aquire M No No 0 13,930 0 83,987.7
4 Mar 21 Sven Dethlefs Restricted Share Units Ordinary Shares Option exercise Dispose M No No 0 13,930 0 27,861
4 Mar 21 Richard Daniell Ordinary Shares Sell Dispose S No Yes 10.5844 7,513 79.52K 20,280
4 Mar 21 Richard Daniell Ordinary Shares Option exercise Aquire M No No 0 15,920 0 27,793

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

11.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2 0 NEW
Opened positions 2 0 NEW
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 1.26B 0 NEW
Total shares 130.45M 0 NEW
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Capital Research Global Investors 130.14M $1.26B NEW
Wellington Management 310.79K $3M NEW
Largest transactions
Shares Bought/sold Change
Capital Research Global Investors 130.14M +130.14M NEW
Wellington Management 310.79K +310.79K NEW

Financial report summary

?
Management Discussion
  • The discussion that follows includes a comparison of our results of operations and liquidity and capital resources for fiscal years 2020 and 2019. For a comparison of our results of operations and financial condition for fiscal years 2019 and 2018, see “Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our 2019 Annual Report on Form10-K,
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
New words: adalimumab, adapt, adapting, African, ago, agreemen, albeit, Alvotech, amplified, Anfinitor, Apixaban, AptensioXR, argument, arm, Ascorbate, Ascorbic, Asian, aspire, Atripla, BCBSM, bellwether, Biden, Brazilian, busin, Bystolic, Cal, capture, Carbamazepine, CAUTIONARY, CECL, celebrate, cerebral, Chloride, chose, circumscribed, Clotrimazole, communicable, conscientiously, conviction, curb, dance, debarment, deceleration, dermatological, detriment, diagnosed, Dimethyl, disciplined, distancing, distinguish, dominant, DSCSA, durability, duringthese, economy, EEA, Efavirenz, Eliquisr, email, emotional, emtricitabine, ensuing, ESG, ess, Etodolac, exclusionary, fear, feel, feeling, female, fifty, Francisco, Goa, guiding, healthy, hesitancy, Humira, hygiene, IFR, Ill, Imiquimod, immunogenicity, imperative, impleme, indicted, indictment, inMarch, inside, irbesartan, issubject, jurisdiction, krona, LAI, learning, lifetime, Lisbon, losartan, mapping, MDI, men, mentoring, MFN, midst, morale, MoviPrep, Nadolol, nebivolol, NOC, nted, numerical, ofproperty, Ointment, online, outbreak, outreach, Pa, palsy, pandemic, PhRMA, play, pleading, pled, PM, postponed, PPE, precautionary, preemption, pride, protectionist, prove, proximity, PSUsgranted, purity, quota, ranitidine, recession, reconsider, redundancy, reinstated, relaunch, reluctance, remotely, repose, resonating, risperidone, Romidepsin, safeguarding, schizophrenia, sending, shape, show, showed, skinny, slower, society, statistical, steeper, strained, Subtopic, survey, survive, Swedish, swelled, tamper, Te, Temozolomide, temporarily, thecourt, Theexpense, theirperformance, thesale, thoughtful, tirelessly, toBB, Tobramycin, toresidual, town, traceability, Truvada, turnover, underscore, uninterrupted, unprecedented, upholding, Upjohn, upper, uptake, upto, va, Virgin, virtual, virtually, Warfarin, wave, week, wellbeing, workplace, Zyclara
Removed: abolishment, actuated, addressed, ADHD, Advair, Aggrenox, Amazon, AmerisourceBergen, announcement, annum, anticompetitive, AOP, appointed, asqui, assured, attempting, Baker, Barr, Barry, BBB, begun, bench, benralizumab, benzoyl, Berkshire, beta, BI, blocking, Boehringer, breath, CAD, cancer, capitalize, capped, Chase, chemotherapy, CHF, children, ciclesonide, cluster, Concerta, conclusion, confirmed, conform, consisting, constant, creditable, declare, declared, declined, deconsolidated, deconsolidation, deem, deliberately, denying, departure, derivatively, devaluation, diligence, dilutive, divert, docket, DuoResp, eleven, Elliot, ELS, episodic, EUR, expanded, exposing, Flovent, Frazer, GBP, gradual, grantor, Grodko, guanfacine, Hathaway, hinder, hip, hydrofluoroalkane, identification, impair, ineffectively, influenced, Ingelheim, insured, Integrating, intensified, interfere, intervene, Intuniv, invalidating, invoiced, irrespective, ixazomib, join, JPMorgan, JPY, Kabi, knee, LABA, language, leasing, levalbuterol, lobby, losing, low, lung, Lupin, matured, McKesson, mesalamine, Modernization, mono, month, Ninlaro, Nordic, opted, ordered, originate, OZ, perception, permanent, permission, permitted, peroxide, Perrigo, persuade, persuasive, pharmacovigilance, PLN, preclude, presiding, prevented, prioritize, punitive, quantification, question, realizing, refundable, rejected, relator, reliably, relocation, remained, repeal, replace, resale, responding, restoring, retroactive, retrospectively, revealed, reverse, saleable, Shire, situated, Slayback, smooth, speaker, stabilizing, substantive, suffered, tam, TD, topical, translate, traumatic, TriCor, underpinning, undo, Unfair, unforeseen, unsealed, USP, utilization, variability, Venezuela, Venezuelan, vi, voluntarily, warehousing, warranty, whistleblower, Wisconsin, withheld, worsen

Patents

GRANT
Utility
Training in dispensing a medicament
6 Apr 21
A medicament-free device (e.g., a smartphone device) for simulating a medicament dispenser may include a sensing device and a processor.
APP
Utility
Position-specific Asymmetric Deuterium Enriched Catecholamine Derivatives and Medicaments Comprising Said Compounds
1 Apr 21
Inventors: Rudolf-Giesbert ALKEN, Frank Schneider
GRANT
Utility
Aerosol device
30 Mar 21
The present invention provides an aerosol device for delivering a pharmaceutical formulation by inhalation via the mouth to the lungs or to the nostril in metered doses comprising: a pressurised aerosol canister including a vial containing a pharmaceutical formulation comprising an active ingredient, a propellant and, optionally, a co-solvent, the aerosol canister further comprising a metering valve having a valve stem; and an actuator for the aerosol canister, the actuator including a delivery outlet and a stem block, the stem block having a receptacle into which the valve stem of the metering valve of the aerosol canister is received and axially located and being displaceable relative to the vial of the aerosol canister to actuate the metering valve of the aerosol canister, a sump extending below the receptacle, the stem block further defining a discharge orifice arranged to direct the pharmaceutical formulation through the delivery outlet, a transfer tunnel having an input opening and an output opening through which a dispensed dose of the pharmaceutical formulation is able to pass from the sump to the discharge orifice, and a land length defining the distance from between the input opening and output opening, wherein the input opening and the output opening have cross-sectional areas of from 0.002 to 0.8 mm2 and the cross-sectional area of the input opening is smaller than the cross-sectional area of the output opening, and wherein the land length is from 0.5 mm to 10 mm.
APP
Utility
Crystalline Siponimod Fumaric Acid and Polymorphs Thereof
25 Mar 21
Disclosed crystalline Siponimod fumaric acid, solid state forms (polymorphs) thereof, processes for preparation thereof and pharmaceutical compositions thereof.
GRANT
Utility
Processes for the preparation of Niraparib and intermediates thereof
23 Feb 21
The present invention relates to novel procedures and novel intermediates useful in the synthesis of Niraparib or any salt thereof.